These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37760979)

  • 21. NTRK fusions in lung cancer: From biology to therapy.
    Harada G; Santini FC; Wilhelm C; Drilon A
    Lung Cancer; 2021 Nov; 161():108-113. PubMed ID: 34563714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic fusions: Targeting NTRK.
    Hagopian G; Nagasaka M
    Crit Rev Oncol Hematol; 2024 Feb; 194():104234. PubMed ID: 38122917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting TRK: A fast-tracked application of precision oncology and future directions.
    Kojadinovic A; Laderian B; Mundi PS
    Crit Rev Oncol Hematol; 2021 Sep; 165():103451. PubMed ID: 34389458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
    Filippi R; Depetris I; Satolli MA
    Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
    [No Abstract]   [Full Text] [Related]  

  • 27. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
    Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
    Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series.
    Iannantuono GM; Riondino S; Sganga S; Rosenfeld R; Guerriero S; Carlucci M; Capotondi B; Torino F; Roselli M
    J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 30. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
    Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
    PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTRK fusions in colorectal cancer: clinical meaning and future perspective.
    Ratti M; Grizzi G; Passalacqua R; Lampis A; Cereatti F; Grassia R; Hahne JC
    Expert Opin Ther Targets; 2021 Aug; 25(8):677-683. PubMed ID: 34488530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
    El-Nassan HB; Al-Qadhi MA
    Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors.
    Bokemeyer C; Vassal G; Italiano A; De La Cuesta E; Hiemeyer F; Fellous M; Marian M
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34568715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.
    Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S
    Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.
    Harada G; Drilon A
    Cancer Genet; 2022 Jun; 264-265():33-39. PubMed ID: 35334340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRK Inhibitors in Non-Small Cell Lung Cancer.
    Harada G; Gongora ABL; da Costa CM; Santini FC
    Curr Treat Options Oncol; 2020 Apr; 21(5):39. PubMed ID: 32328803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
    Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
    Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment.
    Li W; Wen K; Zhu W; Luo S
    Per Med; 2023 Nov; 20(6):485-491. PubMed ID: 37909303
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
    Doz F; van Tilburg CM; Geoerger B; Højgaard M; Øra I; Boni V; Capra M; Chisholm J; Chung HC; DuBois SG; Gallego-Melcon S; Gerber NU; Goto H; Grilley-Olson JE; Hansford JR; Hong DS; Italiano A; Kang HJ; Nysom K; Thorwarth A; Stefanowicz J; Tahara M; Ziegler DS; Gavrilovic IT; Norenberg R; Dima L; De La Cuesta E; Laetsch TW; Drilon A; Perreault S
    Neuro Oncol; 2022 Jun; 24(6):997-1007. PubMed ID: 34850167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
    Elfving H; Broström E; Moens LNJ; Almlöf J; Cerjan D; Lauter G; Nord H; Mattsson JSM; Ullenhag GJ; Strell C; Backman M; La Fleur L; Brunnström H; Botling J; Micke P
    Lung Cancer; 2021 Jan; 151():53-59. PubMed ID: 33310622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.